|
[1]
|
Sung, H., Ferlay, J., Siegel, R., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Siegel, R., Miller, K. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Orr, B. and Edwards, R. (2018) Diagnosis and Treatment of Ovarian Can-cer. Hematology/Oncology Clinics of North America, 32, 943-964. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Matulonis, U., Sood, A., Fallowfield, L., et al. (2016) Ovarian Cancer. Nature Reviews Disease Primers, 2, Article No. 16061. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Gershenson, D., Bodurka, D., Lu, K., et al. (2015) Impact of Age and Primary Disease Site on Outcome in Women with Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. Journal of Clinical Oncology: Official Journal of the American So-ciety of Clinical Oncology, 33, 2675-2682. [Google Scholar] [CrossRef]
|
|
[6]
|
Torre, L., Trabert, B., DeSantis, C., et al. (2018) Ovarian Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 284-296. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Jemal, A., Tiwari, R., Murray, T., et al. (2004) Cancer Statistics, 2004. CA: A Cancer Journal for Clinicians, 54, 8-29. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
du Bois, A., Quinn, M., Thigpen, T., et al. (2005) 2004 Consensus Statements on the Management of Ovarian Cancer: Final Document of the 3rd International Gynecologic Cancer Inter-group Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of Oncology: Official Journal of the Euro-pean Society for Medical Oncology, 16, viii7-viii12. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Perren, T., Swart, A., Pfisterer, J., et al. (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. The New England Journal of Medicine, 365, 2484-2496. [Google Scholar] [CrossRef]
|
|
[10]
|
Banerjee, S., Moore, K., Colombo, N., et al. (2020) 811MO Maintenance Olaparib for Patients (pts) with Newly Diagnosed, Advanced Ovarian Cancer (OC) and a BRCA Mutation (BRCAm): 5-Year (y) Follow-Up (f/u) from SOLO1. Annals of Oncology, 31, S613. [Google Scholar] [CrossRef]
|
|
[11]
|
Wang, L. (2019) Prognostic Effect of Programmed Death-Ligand 1 (PD-L1) in Ovarian Cancer: A Systematic Review, Meta-Analysis and Bioinformatics Study. Journal of Ovarian Research, 12, 37. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Kohan-Ivani, K., Gabler, F., Selman, A., et al. (2016) Role of Di-hydrotestosterone (DHT) on TGF-β1 Signaling Pathway in Epithelial Ovarian Cancer Cells. Journal of Cancer Research and Clinical Oncology, 142, 47-58. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Zheng, L., Qu, J. and He, F. (2016) The Diagnosis and Patholog-ical Value of Combined Detection of HE4 and CA125 for Patients with Ovarian Cancer. Open Medicine (Warsaw, Po-land), 11, 125-132. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Melincovici, C., Boca, A., Uman, S., et al. (2018) Vascular Endothe-lial Growth Factor (VEGF)—Key Factor in Normal and Pathological Angiogenesis. Romanian Journal of Morphology and Embryology, 59, 455-467.
|
|
[15]
|
Stiekema, A., Boldingh, Q., Korse, C., et al. (2015) Serum Human Epididymal Protein 4 (HE4) as Biomarker for the Differentiation between Epithelial Ovarian Cancer and Ovarian Metastases of Gas-trointestinal Origin. Gynecologic Oncology, 136, 562-566. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Guadagni, F., Roselli, M., Cosimelli, M., et al. (1995) CA 72-4 Serum Marker—A New Tool in the Management of Carcinoma Patients. Cancer Investigation, 13, 227-238. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Yang, Z., Zhao, B. and Li, L. (2016) The Significance of the Change Pattern of Serum CA125 Level for Judging Prognosis and Diagnosing Recurrences of Epithelial Ovarian Cancer. Journal of Ovarian Research, 9, 57. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Al-Musalhi, K., Al-Kindi, M., Ramadhan, F., et al. (2015) Valid-ity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer. Oman Medical Journal, 30, 428-434. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Li, K., Pei, Y., Wu, Y., et al. (2020) Performance of Matrix-Assisted La-ser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) in Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis. Journal of Ovarian Research, 13, 6. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Dochez, V., Caillon, H., Vaucel, E., et al. (2019) Biomarkers and Algorithms for Diagnosis of Ovarian Cancer: CA125, HE4, RMI and ROMA, a Review. Journal of Ovarian Research, 12, 28. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Granato, T., Midulla, C., Longo, F., et al. (2012) Role of HE4, CA72.4, and CA125 in Monitoring Ovarian Cancer. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 33, 1335-1339. [Google Scholar] [CrossRef] [PubMed]
|